In a mouse model of MS, treatment with anti-CD19 CAR-T cells resulted in the elimination of meningeal B cell aggregates and exacerbated clinical disease; however, in another B-cell-dependent MS model, anti-CD19 CAR-T cells effectively depleted B cells in both peripheral tissues and the central nervous system (CNS), leading to a reduction in clinical scores and lymphocyte infiltration (68, 69). Here, CD19 is linked to myeloid sarcoma.